IMO-9200 / Aceragen - LARVOL DELTA

Idera Pharmaceuticals: Set to ride a 200% gain in 2014 (SeekingAlpha) - "With the safety and tolerability seen thus far with these results for IMO-8400 Idera has decided to add 12 more patients in an expansion cohort with a higher dosing regimen of 0.6 mg/kg."; Anticipated topline P2 data for expansion cohort end of 2Q 2014; Anticipated clinical development for IMO-9200 H2 2014.

Anticipated P2 data • New molecule • Psoriasis

Idera pharmaceuticals provides development update on IMO-9200, an antagonist of toll-like receptors (GlobeNewswire) -  "Idera Pharmaceuticals, Inc...announced the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease (IBD) at the 2015 Digestive Disease Week Conference (DDW) in Washington...These results demonstrated the potential of orally dosed IMO-9200 as a treatment for inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC)."

Conference • Preclinical • Inflammatory Bowel Disease

IMO-9200: Anticipated expiry of patents in US related to chemical composition and methods of use in 2034 (Idera Pharmaceuticals, Inc) - Annual Report 2016

Patent expiry • Oncology